Related Experiment Video
Updated: Aug 3, 2026

Murine Left Anterior Descending (LAD) Coronary Artery Ligation: An Improved and Simplified Model for Myocardial Infarction
Published on: April 2, 2017
Deoxycytidylate deaminase in the diagnosis of acute myocardial infarction
Abstract:
The diagnostic value of deoxycytidylate deaminase (dCMP) in the diagnosis of acute myocardial infarction (AMI) was examined in 31 healthy controls and 32 patients with proven AMI. Its specificity in normal controls was 93.5%. Its highest levels were measured on the 3rd to 5th post-infarct day, when its sensitivity reached 97.5%. Its diagnostic performance was similar to that of SGOT, total LDH1/LDH2 ratio greater than 1, total CPK and CPK-MB. Its peak levels showed a highly significant correlation (p less than 0.001) with those of the above enzymes. The measurement of dCMP may be a valuable complement in the diagnosis of AMI since this enzyme is not affected by lung infarction or hemolysis. Moreover, since it expresses tissue regeneration rather than destruction it may aid in the assessment of various interventions designed for the promotion of myocardial healing process.
Insights
Deoxycytidylate deaminase (dCMP) shows high diagnostic accuracy for acute myocardial infarction (AMI). This enzyme
Area of Science:
- Biochemistry
- Clinical Diagnostics
- Cardiology
Background:
- Acute myocardial infarction (AMI) diagnosis relies on specific biomarkers.
- Early and accurate diagnosis is crucial for effective treatment and improved patient outcomes.
- Novel biomarkers are continuously being investigated to enhance diagnostic capabilities.
Purpose of the Study:
- To evaluate the diagnostic utility of deoxycytidylate deaminase (dCMP) in patients with acute myocardial infarction (AMI).
- To compare the diagnostic performance of dCMP with established cardiac biomarkers.
- To explore the potential of dCMP in assessing myocardial healing.
Main Methods:
- Assessed dCMP levels in 31 healthy controls and 32 patients with proven AMI.
- Determined specificity and sensitivity of dCMP at different post-infarct stages.
- Correlated peak dCMP levels with established cardiac enzymes like SGOT, LDH, CPK, and CPK-MB.
Main Results:
- dCMP demonstrated high specificity (93.5%) in healthy controls.
- Peak dCMP sensitivity reached 97.5% between the 3rd and 5th post-infarct day.
- dCMP performance was comparable to SGOT, LDH1/LDH2 ratio, total CPK, and CPK-MB, with significant correlations (p < 0.001).
Conclusions:
- dCMP is a valuable complementary biomarker for diagnosing AMI.
- dCMP is unaffected by lung infarction or hemolysis, offering diagnostic advantages.
- Its association with tissue regeneration suggests potential in monitoring myocardial healing interventions.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies

